Table 1.
Laboratory data of patient.
Initial | Final∧ | Reference values | |
---|---|---|---|
WBC | 11.0/nL | 7.8/nL | 3.9–10.6/nL |
Hb | 4.6 g/dL | 8.1 g/dL | 13.5–17.5 g/dL |
Hct | 14.20% | 25.80% | 41–53% |
Plt | 112/nL* | 450/nL | 150–440/nL |
INR | 1.06 | 1.00 | 0.9–1.2 |
aPTT | 50.6 sec | 43.7 sec | 20.1–31.2 sec |
Fibrinogen | 308 mg/dL | NT | 200–400 mg/dL |
VWF : Ag | 8% | 10% | 5–217% |
VWF : RCo | 0% | 0% | 50–150% |
FVIII : C | 2% | 6% | 60–150% |
Cr | 0.9 mg/dL | 0.8 mg/dL | 0.1–1.5 mg/dL |
Albumin | 1.1 g/dL | 2.5 g/dL | 3.5–5.5 g/dL |
Protein/Cr ratio | 2477 mg/g | NT | ≤84 mg/g |
ANA | 1 : 320, homogeneous | NT | <1 : 80 |
Anti-dsDNA | 344 IU/mL | NT | ≤99 IU/mL |
C3 | <30 mg/dL | NT | 90–180 mg/dL |
C4 | <6 mg/dL | NT | 10–40 mg/dL |
CRP | 5.7 mg/L | NT | 0–5.0 mg/L |
ESR | 100 mm/h | NT | 0–15 mm/h |
Reticulocytes | 3.21% | NT | 0.5–2% |
LDH | 290 U/L | NT | 100–210 U/L |
Haptoglobin | 219 mg/dL | NT | 43–212 mg/dL |
Total bilirubin | 0.1 mg/dL | NT | 0.1–1.2 mg/dL |
AST | 19 U/L | NT | 1–40 U/L |
ALT | 9 U/L | NT | 1–40 U/L |
ALP | 49 U/L | NT | 30–115 U/L |
Direct Coombs test | Negative | NT | Negative |
TSH | 10.773 mIU/L | NT | 0.47–6.90 mIU/L |
Free T4 | 1.19 ng/dL | NT | 0.74–2 ng/dL |
WBC: white blood cell count; Hb: hemoglobin; Hct: hematocrit; Plt: platelet count; INR: international normalized ration; aPTT: activated partial thromboplastin time; VWF : Ag: von Willebrand factor antigen; VWF : RCo: von Willebrand factor ristocetin cofactor; FVIII : C: factor VIII procoagulant activity; Cr: creatinine; NT: not tested; ANA: antinuclear antibodies; anti-dsDNA: anti-double stranded DNA antibodies; C3: complement component 3; C4: complement component 4; CRP: C reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; TSH: thyroid stimulating hormone.
∧At last follow-up.
*Plt decreased to 86/nL on the 4th day of admission.